Fidelity International Value Factor ETFFIVA

The Fidelity International Value Factor ETF (FIVA) has spent its first year of life oscillating between the promise of "global value" and the reality of a portfolio that resembles a hedge fund’s abandoned side project. Listed on Nasdaq, FIVA tracks a rules-based index of undervalued companies across developed markets, yet its top holdings reveal a concentration in financials (12.3%) and materials (9.8%), sectors as steady as a three-legged stool on a trampoline.

At its core, FIVA is a wrapper selling a narrative: buy this ETF, and you’re not just owning stocks, you’re owning a curated thesis about value investing’s resurgence. The fund’s SEC filing outlines a methodology that screens for low price-to-book ratios and positive earnings trends, but the resulting basket includes a Swiss pharmaceutical firm, a Canadian energy company, and a UK utility-diversification so broad it risks becoming a mutual fund’s laundry list.

What’s verifiable? FIVA’s expense ratio of 0.35% is documented in FINRA’s Fund Analyzer, though the tool notes the fund has yet to reach $100M in assets, raising questions about liquidity during volatile periods. The fund’s Nasdaq chart shows a 52-week range that’s swung over 25%, a volatility level more akin to individual stocks than a diversified ETF, suggesting the "value" thesis might be getting a crash course in market timing.

The evidence trail remains thin on concrete performance metrics. No dividend yield or total returns are disclosed in the provided sources, leaving investors to parse FIVA’s appeal from its structure alone. Until Fidelity releases harder data, FIVA’s story remains a mix of marketing grit and spreadsheet reality-like a suit bought off the rack but advertised as bespoke.